muraloncology.com (MURA): Price-to-Projected Revenue Ratio

Brandmark of Mural Oncology (MURA)

Mural Oncology plc (MURA) is developing cancer immunotherapy backed by a solid liquidity reserve, which is supported by the projected P/S ratio. The current value of reflects the metric's balance amid a fierce struggle with pharma behemoths for leadership in clinical trials. The business's success depends on the trial results of new molecules and strict cost control during the pre-commercial period.

Mural Oncology PLC - MURA Forward P/S Multiple (period 07/04/2022 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Mural Oncology PLC (MURA)

Initial company analysis:MURA (Mural Oncology PLC)
Manufactured products of Mural Oncology

The investment attractiveness of Mural Oncology plc (MURA) is based on its pricing power derived from unique patented immunotherapeutic molecules. This indicator compares the current market value of the business with expected future sales volumes, allowing the projected market cap-to-revenue ratio to determine whether the asset is overvalued or possesses a fundamental margin of safety for long-term positions.

Competitor analysis for Mural Oncology plc

Forward P/S Multiple ONC (BeiGene Oncology)|Forward P/S Multiple Halozyme Corp HALO|RVMD: Forward Price-to-Revenue Multiple|Ascentage Pharma Group (AAPG) - Forward Price-to-Revenue Multiple|CG Oncology Therapeutics (CGON) - Price-to-Projected Revenue Ratio|Projected Price to Revenue UroGen Pharma URGN|Price-to-Projected Revenue Ratio Bicara Bio|Market Cap to Future Revenue Ratio Personalis Genomics PSNL|Forward P/S Multiple ERAS|Price to Expected Revenue Ratio DCTH|Y-mAbs Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Aura Biosciences Inc (AURA)|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc.)|SLS: Forward P/S Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio tuhurabio.com HURA|Forward P/S Multiple TARA|FATE: Future Price to Revenue|Forward P/S Multiple WHWK (Aadi Bioscience)|TCRX (TScan) - Future Price to Revenue|Champions Oncology, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio XBiotech Inc XBIT|CVM: Forward P/S Multiple|OSTX - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Radiopharm Theranostics Limited|Forward P/S Multiple artivabio.com|Forward Price-to-Revenue Multiple ANL (Adlai Nortye Limited)|Veru - Market Cap to Projected Revenue|Tempest Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio xiliotx.com (XLO)|Renovaro - Forward P/S Multiple|KAPA - Forward P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CytoMed|Price-to-Projected Revenue Ratio curis.com|Forward Price-to-Revenue Multiple Apollomics, Inc. (APLM)|Forward P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Genprex GNPX|Market Cap to Expected Sales Ratio Calidi Bio (CLDI)|sunshinebiopharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Projected Revenue Ratio|Purple Biotech Ltd. - Forward Price to Sales|Price-to-Projected Revenue Ratio AON|Forward P/S Multiple BeiGene Ltd.|Price-to-Projected Revenue Ratio Checkpoint Therapeutics, Inc. (CKPT)|Forward Price-to-Revenue Multiple Elevation Oncology, Inc. ELEV|Forward P/S Multiple ICAD (iCAD Inc.)|IKNA - Forward Price-to-Revenue Multiple|NTBL: Forward Price-to-Revenue Multiple|viracta.com (VIRX) - Forward Price-to-Revenue Multiple|MorphoSys (MOR) - Price-to-Projected Revenue Ratio|NAYA Biosciences Corp (NAYA) - Forward P/S Multiple|AAPGV (Ascentage) - Forward P/S Multiple